Beam Therapeutics EV/EBITDA
¿Qué es el EV/EBITDA de Beam Therapeutics?
El EV/EBITDA de Beam Therapeutics Inc. es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en NASDAQ en comparadas con Beam Therapeutics
¿Qué hace Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Empresas con ev/ebitda similar a Beam Therapeutics
- Castile Resources tiene EV/EBITDA de N/A
- Greenhill & Co Inc tiene EV/EBITDA de N/A
- Cool Link () tiene EV/EBITDA de N/A
- Syntonic tiene EV/EBITDA de N/A
- Merida Minerals Inc tiene EV/EBITDA de N/A
- Golden Meditech tiene EV/EBITDA de N/A
- Beam Therapeutics tiene EV/EBITDA de N/A
- Hummingbird Resources Plc tiene EV/EBITDA de N/A
- Tern Plc tiene EV/EBITDA de N/A
- Magnis Resources tiene EV/EBITDA de N/A
- Fastly Inc tiene EV/EBITDA de N/A
- Soliton tiene EV/EBITDA de N/A
- WeTrade tiene EV/EBITDA de N/A